Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124338 | 0.92 | LMNA (0.51) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL6216656 | 0.88 | NR1H2 (0.47) | ESR2ADORA1NR1H2MAPK1USP2 | |
| Guvacine SCHEMBL22124004 | 0.87 | BLM (0.55) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL3729307 | 0.85 | CHRM3 (0.56) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL19462690 | 0.84 | ADORA1 (0.43) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL20314993 | 0.84 | ESR2 (0.42) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL29234093 | 0.83 | ADORA1 (0.42) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL6218755 | 0.81 | ADORA1 (0.49) | ESR2ADORA1NR1H2MAPK1SMN1; SMN2 | |
| SCHEMBL12519920 | 0.81 | ESR2 (0.47) | ESR2ADORA1NR1H2MAPK1USP2 | |
| SCHEMBL18556946 | 0.81 | ESR2 (0.50) | ESR2ADORA1NR1H2MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025130765-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-06-26 | — | — | WO | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-6894168-B2 | Carbamoyl tetrahydropyridine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-17 | — | — | US | disclosed |
| EP-1449843-A1 | Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | NAKAZATO ATSURO (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6600038-B1 | Intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF. involving Corticotropin Releasing Factor (CRF), such as depression, anxiety, | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1176146-A1 | CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-01-30 | — | — | EP | disclosed |
| US-6046214-A | USEFUL IN TREATMENT AND/OR PREVENTION OF DIABETES, AND ESPECIALLY NON-INSULIN DEPENDENT DIABETES (NIDDM OR TYPE 2 DIABETES) INCLUDING OVERNIGHT OR MEAL TREATMENT AND TREATMENT OR PREVENTION OF LONGTERM COMPLICATIONS, SUCH AS RETINOPATHY | NOVO NORDISK A/S (DK) | 2000-04-04 | — | — | US | disclosed |
| EP-0983239-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050359-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-11-12 | — | — | WO | disclosed |
| US-5134146-A | SUBSTITUTED OXADIAZOLES AND THIADIAZOLES FOR USE IN THE TREATMENT OF GLAUCOMA | MERCK SHARP AND DOHME LTD. (GB) | 1992-07-28 | — | — | US | disclosed |
| EP-0459568-A2 | Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | ESR2 2512/4885ADORA1 1035/4885NR1H2 2483/4885 |
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | CNR1, CRHR1, CRH | ESR2 1696/4885ADORA1 1986/4885NR1H2 383/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | ESR2 2760/4885ADORA1 2830/4885NR1H2 2265/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ESR2 893/4885ADORA1 2099/4885NR1H2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.